Clinical trials: Cushing's Disease
Adrenal Gland Hyperfunction, Adrenal Gland Hypofunction
Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency
Corticotropin Releasing Hormone (CRH) is a hypothalamic hormone made up of 41 amino acids. Amino acids are proteins that when combined make up different substances, like hormones.
- Conditions
- Adrenal Gland Hyperfunction, Adrenal Gland Hypofunction, Cushing's Syndrome, Healthy
- Trial name
- NCT00001180
- Testing
- Ovine Corticotropin-Releasing Hormone (oCRH)
- Where
- United States
- Volunteers
- 2,250 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Cushing Disease
Hair Cortisol and Cushing's Disease
The biochemical tools usable to assess the control of hypercortisolism in patients with Cushing's disease receiving medical treatments are debatable.
- Trial name
- HAIRCUSH (NCT04201444)
- Testing
- Patient group, Remission control group, Bilateral surrenalectomy control group
- Where
- 7 sites in France
- Volunteers
- 51 people
- Sponsor
- University Hospital, Bordeaux
Cushing Disease
Use of [18F]FET PET-MRI to Improve Detection of Pituitary Adenomas in Cushing's Disease
In ACTH-dependent hypercortisolism it is important to distinguish between Cushing's disease (CD), with ACTH production by a pituitary neuroendocrine tumour (PitNET) and Cushing's syndrome (CS), with ectopic ACTH production.
- Trial name
- FIND (NCT07108244)
- Testing
- [18F]FET PET-MRI
- Where
- 2 sites in Netherlands, Switzerland
- Volunteers
- 43 people
- Sponsor
- University Hospital, Basel, Switzerland
Cushing's Disease, Cushing's Syndrome
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
This is a compassionate use study. In addition to providing compassionate use access to mifepristone, objectives of the study will be to evaluate the safety and utility of mifepristone in the treatment of the signs and symptoms…
- Trial name
- NCT01371565
- Testing
- Mifepristone
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- Corcept Therapeutics
Hypercorticism
Patient and Partner Perception After Remission of Cushing's Syndrome
Hypercortisolism leads to long term physical and cognitive sequelae. This also holds true for quality of life, even several years after remission.
- Trial name
- CUSHING (NCT03607474)
- Testing
- Questionnaires of life quality for patients, Questionnaires of life quality for caregivers
- Where
- France
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Cushing's Syndrome
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Participants in study C-1073-400 (NCT00569582) will be invited to participate in this extension study to examine the long term safety of mifepristone in the treatment of the signs and symptoms of endogenous Cushing's syndrome.
- Trial name
- NCT00936741
- Testing
- mifepristone
- Where
- 15 sites in United States
- Volunteers
- 30 people
- Sponsor
- Corcept Therapeutics
Developmental Bone Disease, Dwarfism
Study of Skeletal Disorders and Short Stature
This study will determine the genes responsible for skeletal dysplasias (disorders of the skeleton) and short stature and define the range and type of medical problems they cause over time.
- Conditions
- Developmental Bone Disease, Dwarfism, Skeletal Dysplasias
- Trial name
- NCT00001754
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Cushings Disease
Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease
This is a non-interventional, multinational, multi-center post-marketing study, to further document the safety and efficacy of pasireotide s.c. administered in routine clinical practice in patients with Cushing's disease.
- Trial name
- NCT02310269
- Testing
- Pasireotide
- Where
- 54 sites in United States, Canada and 9 more
- Volunteers
- 152 people
- Sponsor
- RECORDATI GROUP
Cushing's Syndrome, Insulin Resistance
Insulin Sensitivity and Substrate Metabolism in Patients With Cushing's Syndrome
The purpose of this study is to investigate the effect og chronic elevated levels of cortisol on metabolism and insulin sensitivity.
- Trial name
- NCT00682084
- Testing
- Surgery
- Where
- Denmark
- Volunteers
- 1 people
- Sponsor
- University of Aarhus
Cushing Syndrome
Quality of Life, Fatigue and Cognitive, Affective and Emotional Dysfunction in Patients With Cushing's Syndrome
This is a prospective, multi-center, case-control study where neurocognitive function will be evaluated in 36 patients with Cushing syndrome (CS) and 36 controls matched for age, gender and education.
- Trial name
- NCT03211624
- Where
- 3 sites in Netherlands, Spain and 1 more
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Göteborg University
Cushing Disease, DVT
Postoperative Thrombosis Prevention in Patients With CD
Patients with Cushing disease was randomized to 2 groups. After surgery, the patients were managed with mechanical prevention or mechanical prevention plus anticoagulant drugs(LMWH followed by rivaroxaban), VTE was observed 24h…
- Conditions
- Cushing Disease, DVT, Pulmonary Embolism
- Trial name
- PIT-CD (NCT04486859)
- Testing
- LMWH/Rivaroxaban, IPC
- Where
- 7 sites in China
- Volunteers
- 206 people
- Sponsor
- Huashan Hospital
Cushing Syndrome, Cushing Disease
Open-label Treatment in Cushing's Syndrome
This is a long-term, open-label extension study of levoketoconazole in participants with endogenous Cushing's Syndrome.
- Trial name
- OPTICS (NCT03621280)
- Testing
- Levoketoconazole
- Where
- 30 sites in United States, Bulgaria and 9 more
- Volunteers
- 51 people
- Sponsor
- Cortendo AB
Cushing Syndrome
Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)
Cushing syndrome (CS) is an endocrine disorder caused by chronic exposure to glucocorticoid (GC) excess. Endogenous CS has an estimated incidence of 0.2 to 5.0 cases per million per year and prevalence of 39 to 79 cases per…
- Trial name
- NCT04543253
- Testing
- MUSE biofeedback
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- Mayo Clinic
Cushing Syndrome, Endocrine Disease
New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome
Cushing Syndrome is an endocrine disorder causing an over production of the hormone cortisol. Cortisol is produced in the adrenal gland as a response to the production of corticotropin (ACTH) in the pituitary gland.
- Trial name
- NCT00001849
- Testing
- Pentetreotide, 18F-DOPA, CT scan
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Cushing's Syndrome, Postoperative
Contralateral Adrenal Volume Predicts Duration of Postoperative Steroid Replacement Therapy in Non-ACTH-dependent Hypercortisolism
To identify preoperative factors influencing the duration of steroid replacement therapy after adrenalectomy/adrenal-sparing surgery in patients with non-ACTH-dependent hypercortisolism.
- Conditions
- Cushing's Syndrome, Postoperative, Glucocorticoid, Prediction
- Trial name
- NCT07282223
- Testing
- observational diagnostic model development
- Where
- China
- Volunteers
- 121 people
- Sponsor
- Peking University First Hospital
Cushing Syndrome
Observational Registry on Patients With Endogenous CS to Document Safety and Effectiveness of Ketoconazole.
This is a non-interventional, prospective, multinational, multicentre, observational study, in which data collected are those derived from routine clinical practice via an European registry on CS: ERCUSYN.
- Trial name
- KetoPASS (NCT04872920)
- Where
- 6 sites in Croatia, France and 2 more
- Volunteers
- 200 people
- Sponsor
- HRA Pharma
Cushing's Syndrome, Healthy
Study of Cushing's Syndrome Not Related to ACTH Production
This study is designed to provide information about the cause of two unusual types of Cushing's syndrome and to evaluate quality of life before and after cure of the disease.
- Trial name
- NCT00006278
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Cushing's Disease, Corticotroph Adenoma
Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor
This study was designed to check the efficacy of a new oral medical drug treatment, namely Cabergoline, for the treatment of Cushing Disease due to pituitary adenoma. Background: Cabergoline is a Dopamine 2 receptor agonist.
- Trial name
- NCT00889525
- Testing
- Cabergoline
- Where
- India
- Sponsor
- Seth Gordhandas Sunderdas Medical College
Cushing Syndrome, Adrenal Insufficiency
Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid Disorders
This is a multicentric, prospective, intervention study on circadian genes expression in peripheral blood mononuclear cells as biomarkers of circadian rhythm derangement in patients affected by alterations of endogenous…
- Conditions
- Cushing Syndrome, Adrenal Insufficiency, Cushing Disease, Addison Disease
- Trial name
- CHROnOS (NCT04374721)
- Testing
- circadian gene expression evaluation
- Where
- Italy
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza
Cushing Syndrome
Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome
Multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing's syndrome.
- Trial name
- NCT03708900
- Testing
- LCI699
- Where
- 15 sites in United States, Belgium and 5 more
- Volunteers
- 12 people
- Sponsor
- RECORDATI GROUP